Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated MelanomaGeorgina V. Long, John M. Kirkwood, Caroline Dutriaux et al.|New England Journal of Medicine|2017Cited by 1.5k
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaReinhard Dummer, Dirk Schadendorf, Axel Hauschild et al.|New England Journal of Medicine|2020Cited by 406
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600–Mutant Stage III MelanomaAxel Hauschild, Georgina V. Long, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 255
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V. Long, Reinhard Dummer, Axel Hauschild et al.|New England Journal of Medicine|2024Cited by 123